AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.